As per industry analysis on vancomycin by Fact.MR, a market research and competitive intelligence provider, the global market is predicted to expand at a CAGR of 5.8% over the forecast period and reach US$ 465.1 Mn by 2027.
The human body is home to a wide range of microorganisms. Staphylococcus aureus, a gram-positive bacterium that is most typically found on the human skin and nasal passages, is one of them. The market for vancomycin is developing due to increasing prevalence of this infection. Increasing government and non-government awareness campaigns are also expected to contribute to market growth.
The global vancomycin market is being driven by increased incidence of diseases caused by vancomycin-resistant Staphylococcus aureus (VRSA), and poor sanitation, which, in turn, increases the risk of hospital-acquired infections.
VRSA infections can be treated with a range of commercially available drugs, but maintaining basic sanitary conditions, including wound care, hand washing before and after direct contact with patients, and the use of disposable gloves, is the most effective strategy for preventing the spread of VRSA.
Vancomycin is used as a first-line and second-line treatment, depending on the diseases for which it is prescribed. The global market for vancomycin is predicted to rise over the next years owing to increasing demand for antibiotics. The market is reliant on the number of processed prescriptions for cases, which is increasing at an unprecedented rate.
Key Takeaways from Market Study
- Global vancomycin market to reach US$ 1 valuation Mn by 2027.
- Market in Germany projected to rise at a CAGR of 4% over the forecast period.
- Market in Canada to record 4.6% CAGR over the forecast period of 2021-2027.
- China vancomycin market forecast to reach size of US$ 102.3 Mn by 2027.
“Healthcare beneficiaries play a key part in the movement, influencing corporations to develop pharmaceuticals for comprehensive treatment. Rising initiatives by government organizations for the development of novel drugs and treatments are supporting vancomycin market growth,” says a Fact.MR analyst
To increase their market position across geographies, vancomycin suppliers are investing in the research and development of new medicines. Key players are also working hard to secure regulatory approvals for their products.
- In 2019, Rutgers University researchers identified two genes that make illnesses such as VRSA resistant to therapy.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global vancomycin market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2027.
The study divulges essential insights on the market on the basis of type (daptomycin, linezolid, quinupristin, ampicillin, chloramphenicol, and others) and application (sepsis, lung infection, skin soft tissue infection, colitis & intestinal inflammation, and other infections), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Fact.MR’s Domain Knowledge in Healthcare
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
For more information, refer to our market research report or contact the PR author.